To date, prophylaxis in haemophilia has consisted of the intravenous administration two or three times per week of standard half-life (SHL) plasma-derived or recombinant FVIII/FIX concentrates, a highly demanding schedule that has led to lack of adherence due to a variety of factors and barriers [7]. This evidence concerns the gene F8 and hemophilia.